JO
SBFM

John Overdeck’s Sunshine Biopharma SBFM Stock Holding History

John Overdeck’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,140
Closed -$31.9K – 4376
2025
Q3 		$31.9K Buy
+2,140
New +$31.7K ﹤0.01% 3567
2024
Q2 		– Sell
-1
Closed -$1.16K – 3288
2024
Q1 		$1.16K Buy
+1
New +$2.94K ﹤0.01% 2983
2022
Q4 		– Sell
-2
Closed -$29K – 3043
2022
Q3 		$29K Buy
+2
New +$43.4K ﹤0.01% 2361

Other funds holding SBFM

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $3.05B AUM 18.61% 1-Year Est. Return

John Overdeck's SBFM Position: Q4 2025 in Review

John Overdeck sold out of Sunshine Biopharma (SBFM) in Q4 2025, closing a stake of 2,140 shares — an estimated $31.9K sold.

John Overdeck first reported a position in SBFM in Q3 2022 and held it in 3 quarters. The position peaked at $31.9K in Q3 2025. 9 funds tracked by Wall St. Rank hold SBFM as of Q4 2025.

  • John Overdeck reported no remaining Sunshine Biopharma position as of Q4 2025 after selling out during the quarter.
  • John Overdeck sold 2,140 Sunshine Biopharma shares in Q4 2025, an estimated $31.9K.
  • John Overdeck first reported a position in Sunshine Biopharma in Q3 2022 and held it in 3 quarters.
  • John Overdeck's Sunshine Biopharma position peaked at $31.9K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q4 2025.

Based on Two Sigma Investments's 13F filing for Q4 2025, filed 17 Feb 2026.